| First Author | Popova I | Year | 2017 |
| Journal | Neurobiol Dis | Volume | 106 |
| Pages | 244-254 | PubMed ID | 28709994 |
| Mgi Jnum | J:268702 | Mgi Id | MGI:6267206 |
| Doi | 10.1016/j.nbd.2017.07.012 | Citation | Popova I, et al. (2017) Metabolic correction by pyruvate halts acquired epilepsy in multiple rodent models. Neurobiol Dis 106:244-254 |
| abstractText | Metabolic intervention strategy of epilepsy treatment has been gaining broader attention due to accumulated evidence that hypometabolism, manifested in humans as reduced brain glucose consumption, is a principal factor in acquired epilepsy. Therefore, targeting deficient energy metabolism may be an effective approach for treating epilepsy. To confront this pathology we utilized pyruvate, which besides being an anaplerotic mitochondrial fuel possesses a unique set of neuroprotective properties as it: (i) is a potent reactive oxygen species scavenger; (ii) abates overactivation of Poly [ADP-ribose] polymerase 1 (PARP-1); (iii) facilitates glutamate efflux from the brain; (iv) augments brain glycogen stores; (v) is anti-inflammatory; (vi) prevents neuronal hyperexcitability; and (vii) normalizes the cytosolic redox state. In vivo, chronic oral pyruvate administration completely abolished established epileptic phenotypes in three accepted and fundamentally different rodent acquired epilepsy models. Our study reports metabolic correction by pyruvate as a potentially highly effective treatment of acquired epilepsies. |
